Rapamycin + Trametinib – Extended Mouse Lifespan 30%

A May 2025 paper in Nature Aging landed with unusual force, even for a field accustomed to bold claims. Researchers at the Max Planck Institute combined two drugs (rapamycin and trametinib) and found that together they extended mouse lifespan by around 30%, well beyond what either drug achieves alone. If you follow longevity science at all, you heard about this one.

Here’s what the study actually showed, what it means for the biology of aging, and why the gap between mouse data and human application is bigger than the headlines suggest.

The Study That Made Headlines: Nature Aging, May 2025

Linda Partridge, Cathy Gronke, and colleagues at the Max Planck Institute for Biology of Ageing published results from what is, by any measure, a serious study. Over 800 mice. Four arms: control, rapamycin alone, trametinib alone, and the combination. Treatment started at six months of age, roughly equivalent to early middle age in humans.

The headline result: the combination extended median lifespan by approximately 30%, more than either drug in isolation. That’s a bigger number than almost anything the field has produced in a mammal.

Why it got attention isn’t hard to explain. Rapamycin has been the gold standard of pharmacological lifespan extension in mice for over a decade. Trametinib is newer to the longevity scene. Seeing both together produce synergistic effects, not just additive ones, is scientifically meaningful. It points toward something real about how these pathways interact.

Rapamycin and Trametinib: Two Drugs, Two Targets

To understand why this combination works, you need to understand what each drug does and why hitting two targets matters.

Rapamycin hits mTORC1, a central switch for cell growth, protein synthesis, and autophagy. Suppress it, and cells swap growth mode for maintenance mode. Autophagy ramps up, senescent cell clearance improves, and a range of age-related processes decelerate. The NIH Interventions Testing Program (ITP) has replicated these effects across multiple labs, finding roughly 23-26% median lifespan extension in mice. It is the most consistently validated geroprotector in mammals.

Trametinib works on a completely different pathway. It inhibits MEK, a kinase in the Ras/MEK/ERK signaling cascade, the network that handles nutrient, growth factor, and stress signals. Chronic overactivity in this pathway drives inflammation, aberrant cell proliferation, and accelerated tissue aging, all hallmarks of the aging process. Trametinib had shown lifespan extension in Drosophila before this study moved it into mouse territory.

The key insight is that both pathways, mTOR and Ras/MEK/ERK, are part of the broader nutrient and growth signaling network that governs aging. They’re different nodes in the same system. Hitting one node produces benefits. Hitting two distinct nodes, without simply doubling the dose of either, gives you something more. The combination addresses mechanisms the other drug leaves untouched.

The Lifespan Numbers: What the Study Found

The results broke down like this, roughly speaking:

Rapamycin alone (consistent with ITP data): females saw about 26% median lifespan extension, males about 23%.

Trametinib alone: females about 7% median, males about 10% median; maximal lifespan extended by around 16%.

The combination: females about 35% median (and around 32% in maximal lifespan), males about 27% median (around 26% maximal).

That’s not just addition. If you add trametinib’s ~7-10% to rapamycin’s ~23-26%, you’d expect somewhere around 30-36%. The combination lands above or at the high end of that range, which is notable. But more importantly, the study found gene expression changes in combination-treated mice that neither drug produced on its own. This is synergy in a biological sense, not just more of the same.

One other detail worth noting: the dosing schedules differed. Rapamycin was given intermittently, every other week. Trametinib was continuous. Whether those specific schedules drove the synergy or whether other schedules would work is an open question. Dosing protocol may matter more than researchers fully understand yet.

Healthspan: What Actually Improved

Lifespan numbers are easy to misread. Longer life without better health is not the goal. The study looked at healthspan too, and the findings are worth paying attention to.

Chronic inflammation in tissue and the brain was reduced in combination-treated mice. Tumor onset was meaningfully delayed: liver and splenic tumors appeared in over 60% of control mice, compared to 35-45% in the combo group. Cardiovascular markers improved, including a preservation of youthful QT intervals in males and changes in resting heart rate. Metabolic function, measured by respiratory exchange ratio, improved in older males.

There’s a critical nuance here. Most combination-treated mice still died of cancer. This is common in aged mice generally. What’s significant is that when researchers excluded cancer deaths from the analysis, the survival advantage of the combination persisted. Other mechanisms beyond tumor suppression are contributing to the lifespan benefit. The drugs aren’t just slightly delaying the same causes of death. They’re slowing something more fundamental.

Side Effects: What the Study Actually Found

This section matters and deserves honesty.

Rapamycin’s track record includes some known problems: hyperglycemia, lipidosis, and shifts in lean mass, particularly in females. The study found that adding trametinib to rapamycin did NOT worsen these effects. That is genuinely good news. The combination doesn’t compound rapamycin’s downside.

The catch: it also doesn’t fix it. Adding trametinib doesn’t resolve rapamycin’s existing metabolic issues. If you’re concerned about rapamycin’s effects on blood sugar and body composition, trametinib isn’t the answer.

Trametinib carries its own risk profile from its use in oncology. Dermatologic side effects including rash are common in cancer patients. Hepatic and ocular effects have been observed. At the lower doses used in longevity research, these effects may be less pronounced, but they’re not fully characterized at these doses. The honest answer is: we don’t yet know what trametinib’s side effect profile looks like in a longevity context.

Both drugs were developed as cancer therapeutics and are used at much higher doses for that purpose. That context doesn’t disappear when you talk about longevity applications. The pharmacology doesn’t change because the intention does.

What This Means for Humans

The lead researcher, Linda Partridge, was direct about it: “We do not expect a similar extension to human lifespans as we found in mice.”

That’s the lead researcher, not a skeptic. The person who ran the study is telling you the 30% number doesn’t translate.

Several reasons explain why. Mice have much shorter lifespans, and aging biology in short-lived mammals differs in meaningful ways from humans. Mouse tumor biology is different. Drug metabolism and pharmacokinetics differ substantially. And the specific tumor types that kill mice frequently are not the same ones that dominate human mortality. A drug combination that delays splenic lymphoma in a mouse may or may not do anything useful against cardiovascular disease or Alzheimer’s.

That said, both drugs are FDA-approved for other conditions. Rapamycin is used in transplant medicine for immunosuppression. Trametinib is approved for melanoma and non-small cell lung cancer with BRAF V600 mutations. FDA approval for one indication does not mean safety or efficacy for a completely different one.

Biohackers are already experimenting with trametinib off-label. That impulse is understandable. The frustration with slow clinical timelines is real. But trametinib has an oncology-grade side effect profile. It wasn’t developed to be taken indefinitely at low doses by healthy middle-aged people. There is no human longevity data. No safety data at longevity doses. No long-term follow-up. This is prescription territory, and the honest framing is: the evidence gap is large enough that jumping ahead of clinical trials carries risk that isn’t yet quantifiable.

The researchers want clinical trials. That’s the right next step.

Practical Takeaways

Don’t source trametinib online and self-medicate. The study is not a protocol. It’s a biological proof of concept that warrants controlled human trials.

If you’re already using rapamycin for longevity under medical supervision, adding trametinib is not supported by current evidence. It introduces a second drug with its own risk profile, and no human data exists to inform how that combination behaves in people over time.

The fundamentals still apply. Neither drug, alone or in combination, replaces consistent exercise, adequate sleep, and decent nutrition. The combination doesn’t make those irrelevant. That framing shouldn’t need repeating, but it does.

What you should actually watch for is clinical trial announcements. The ITP and NIA Interventions Testing Program are the most credible channels for this kind of research moving into humans. Follow those, not biohacker forums, for the signal on whether this combination is ready for human use.

FAQ

1. Is the 30% lifespan extension real? In mice, yes. The study was conducted at scale, across multiple cohorts, and the results are consistent with biological mechanisms rather than statistical noise. Whether anything close to that translates to humans is a separate question, and the researchers themselves are cautious about it.

2. Can I take trametinib for longevity? It’s FDA-approved for melanoma, not for longevity. Off-label use is possible but carries risks that are poorly characterized at low doses taken long-term. Without medical supervision and a clear understanding of your own health status, this is not a reasonable self-experiment.

3. What is the difference between rapamycin alone vs. the combination? Rapamycin inhibits mTORC1. The combination adds trametinib, which hits MEK in a parallel signaling pathway. The study found gene expression changes in the combination group that neither drug produces on its own, indicating genuine biological synergy rather than just additive dosing effects. The combination outperformed either drug in both median and maximal lifespan.

4. Does trametinib have the same side effects as rapamycin? No, they’re different. Rapamycin’s main concerns include hyperglycemia, lipidosis, and potential immune suppression. Trametinib’s known effects from oncology use include skin rash, liver enzyme elevation, and ocular issues. In the mouse study, the combination did not worsen rapamycin’s side effects, but trametinib adds its own profile on top.

5. Why did the combination produce gene expression changes that neither drug produced alone? Because they target different nodes in an interconnected signaling network. When mTOR and MEK are both inhibited simultaneously, the cellular response involves pathways that neither inhibition triggers independently. The network responds to the combination as a distinct input, not just as doubled pressure on one point.

6. Are there other drug combinations being studied for longevity? Yes. The ITP has tested rapamycin with acarbose and with 17-alpha-estradiol, among others. Senolytic combinations like dasatinib plus quercetin have received attention. The field is moving toward combination approaches precisely because single-target interventions appear to have ceiling effects.

7. Is rapamycin + trametinib available through longevity clinics? Rapamycin off-label for longevity is available through some physicians and longevity clinics, most commonly in the US. Trametinib for longevity is not. As of 2026, no clinical protocol exists for this combination in humans outside of research settings. Any clinic offering it would be operating without supporting human data.